StockNews.com lowered shares of Oramed Pharmaceuticals (NASDAQ:ORMP – Free Report) from a buy rating to a hold rating in a report released on Tuesday morning.
Separately, HC Wainwright reissued a neutral rating on shares of Oramed Pharmaceuticals in a report on Monday.
Read Our Latest Research Report on ORMP
Oramed Pharmaceuticals Stock Down 0.8 %
Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.21. Equities analysts expect that Oramed Pharmaceuticals will post 0.11 EPS for the current fiscal year.
Institutional Trading of Oramed Pharmaceuticals
Institutional investors have recently modified their holdings of the business. XTX Topco Ltd bought a new stake in Oramed Pharmaceuticals during the 2nd quarter valued at $40,000. Assenagon Asset Management S.A. bought a new stake in shares of Oramed Pharmaceuticals during the 1st quarter valued at $54,000. Virtu Financial LLC bought a new stake in shares of Oramed Pharmaceuticals during the 1st quarter valued at $68,000. Dimensional Fund Advisors LP lifted its holdings in Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Oramed Pharmaceuticals by 89.0% in the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares during the period. 12.73% of the stock is currently owned by hedge funds and other institutional investors.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Featured Articles
- Five stocks we like better than Oramed Pharmaceuticals
- Investing in Construction Stocks
- 3 Leveraged ETFs to Multiply Returns
- Options Trading – Understanding Strike Price
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- The How and Why of Investing in Gold Stocks
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.